Antiestrogen action in the uterus: biological ineffectiveness of nuclear bound estradiol after antiestrogen.
These studies attempt to analyze the basis of the estrogenic and antiestrogenic action of three nonsteroidal clomophene-type compounds as monitored by their ability to bind to immature rat uterine cytoplasmic estrogen receptor, transfer receptor sites to the nucleus, and elicit estrogenic responses (increased uterine weight and induction of the synthesis of a specific uterine protein, called induced protein, or "IP"), and by their ability to antagonize the effects of estradiol on these receptor interactions and uterine responses. Both CI-628 (CI) and U-11, 100A (UA) [50 mug] elicit slight IP induction at 1-2 hand give pronounced uterine weight increases at 24 h but feeble increases at 72 h (3 single daily injections). Both bind to cytosol, and effect the transfer of receptor sites to the nucleus, which may account for the estrogenicity of these compounds. Both CI and UA give rapid (by 2-4 h), prolonged (for over 24 h), and complete blockage of estradiol-stimulated treatment abolishes short-term estradiol-stimulated uterine weight increase and antagonizes the 72 h estradiol-stimulated uterine weight response to the level attributable to the antiestrogen alone. MER-25, at the same dose (50 mug), had no estrogenic or antiestrogenic activity. Both CI and UA rapidly deplete the cytoplasmic estrogen binding capacity, reducing it to barely detectable levels for 24-42 h. Although during this period, no IP or uterine wet weight response can be elicited by estradiol, administration of saturating levels of [3H]estradiol in vivo or in vitro results in the appearance of considerable [3H]estradiol in the nucleus, bound to a macromolecule sedimenting identically with that of the nuclear receptor-estradiol complex (5.5S) formed in the absence of prior antiestrogen exposure. Hence, the estradiol which becomes bound in the nucleus after antiestrogen is biologically ineffective. The return of IP responsiveness after antiestrogen correlates well with the level of cytoplasmic receptor capable of translocation to the nucleus, and not with the nuclear estradiol uptake capacity, Presumably, then, the antiestrogenic action of CI and UA results from their depletion of cytoplasmic receptor sites and not from their ability to block specific estradiol-nuclear receptor binding per se. These studies indicate that one should be cautious in assuming that the magnitude of an estrogen response is necessarily related to the level of estrogen receptor complex in the nucleus.
D000818:Animals; D001667:Binding, Competitive; D002250:Carbon Radioisotopes; D002467:Cell Nucleus / Q000378:metabolism; D002499:Centrifugation, Density Gradient; D004958:Estradiol / Q000494:pharmacology*; D004965:Estrogen Antagonists; D004978:Ethamoxytriphetol / Q000494:pharmacology*; D000431:Ethanol / Q000031:analogs & derivatives*; D005260:Female; D007930:Leucine / Q000378:metabolism; D009256:Nafoxidine / Q000494:pharmacology*; D009594:Nitromifene / Q000494:pharmacology*; D009929:Organ Size; D014176:Protein Biosynthesis; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D011956:Receptors, Cell Surface; D014316:Tritium; D014599:Uterus / Q000378:metabolism
D002250:Carbon Radioisotopes; D004965:Estrogen Antagonists; D011759:Pyrrolidines; D011956:Receptors, Cell Surface; D014316:Tritium; D000431:Ethanol; D009256:Nafoxidine; D004958:Estradiol; D009594:Nitromifene; D004978:Ethamoxytriphetol; D007930:Leucine